Premium
An in‐house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV‐1
Author(s) -
Lee Chun Kiat,
Lee Hong Kai,
Loh Tze Ping,
Sethi Sunil Kumar,
Koay Evelyn SiewChuan,
Tang Julian WeiTze
Publication year - 2012
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.23202
Subject(s) - genotyping , virology , drug resistance , sanger sequencing , biology , population , reverse transcriptase , hiv drug resistance , hiv 1 protease , mutation , genotype , genetics , human immunodeficiency virus (hiv) , protease , medicine , polymerase chain reaction , gene , viral load , antiretroviral therapy , biochemistry , environmental health , enzyme
Genotyping for HIV drug resistance is costly and beyond the means for many Southeast Asian patients, who are self‐funded. This prompted the development of a more cost‐effective, in‐house assay for an ethnically diverse, Southeast Asian population at the National University Hospital in Singapore, using Sanger‐based sequencing. Plasma samples from 20 treatment‐failure patients with a broad spectrum of HIV drug resistance mutations were used to validate this assay clinically. Blinded testing gave concordant results for 7/7 (100%) protease drug resistance‐related mutations, including one major and six minor mutations, and 111/116 (95.7%) reverse‐transcriptase (RT) drug resistance‐related mutations, including 65 nucleoside RT inhibitors (NRTI) and 46 non‐nucleoside RT inhibitors (NNRTI) mutations. There were five discordant results, involving three NRTI‐ and two NNRTI‐resistance‐associated mutations. Highly conserved primers designed to have a wide coverage of the HIV pol gene (covering the entire protease and 395 codons of the RT region) enabled efficient multi‐ethnic population‐based genotyping. Reagents for this in‐house test cost around 60% less than those for commercially available assays (SGD150 vs. SGD350 per sample). In addition, this assay also identified mutations located within the C‐terminal domain (codons 312–560) of RT that are beyond the reach of most published and commercial GRTs. Currently, most research on C‐terminal drug‐resistance‐related mutations has been conducted on HIV subtype B infections. Therefore this assay enables further study of these C‐terminal mutations in Southeast Asian populations, where there is a high prevalence of CRF01_AE and other non‐subtype B HIV infections. J. Med. Virol. 84:394–401, 2012. © 2011 Wiley Periodicals, Inc.